Protect yourself with personalised cancer prevention

Detect your genetic risks early and get actionable medical advice for prevention to protect your health.

Prostate cancer prevention for men Learn more

Breast cancer prevention for women Learn more

Supported by

One in four women and one in three men will develop cancer in their lifetime. We need to take action early to protect our health.

Next-generation cancer prevention considers your risk profile

Common cancers and related deaths can often be prevented with timely measures. Personalised cancer prevention with genetic risk assessment can give early warning to women and men at risk even if there is no cancer in the family. It guides you towards tailored screening and prevention based on personal risk level.

Learn more

Personalised breast cancer prevention

Breast cancer is the most common cancer in women, affecting 1 in 7 women in their lifetime.
1 in 5 breast cancer cases are diagnosed in women under 50, but screening programme start at age 50. Early prevention is crucial.
Genetic risk testing helps to evaluate your risk level and provides a personalised medical prevention plan to reduce your risks.
Personalised breast cancer prevention is recommended for all women aged 30 and above to identify higher risks early and start personalised screening programme years before NHS screening programme begins to protect your health. Perfect for health-conscious women, with or without a family history of cancer.

Learn more

Personalised prostate cancer prevention

Prostate cancer is the most common cancer in men. More than 55 000 new cases of the disease are diagnosed in the UK every year, and around 12 000 men die from prostate cancer each year.
About 58% of prostate cancer risk is inherited, even without any visible warning signs such as a family history of cancer.
Standard PSA-based screening may miss these high genetic risk cases, as PSA levels can remain normal even when cancer is already developing.
Genetic risk testing helps to evaluate your inherited risk and provides a personalised medical prevention plan to reduce your risks.
Recommended for men aged 40 and above.

Learn more

Here’s what you’ll learn:

What is your genetic risk level for the most common cancer in men and women
When should you begin cancer screening, and how often
Are there additional measures you can take to lower your risk
What proactive measures can you adopt to reduce your likelihood of developing cancer
What changes or symptoms should you monitor
What should your doctor know

Powered by Innovative Polygenic Risk Score (PRS)

PRS is an innovative, non-intrusive method for predicting disease risk to enable personalised prevention. The use of PRS genetic tests in clinical practice represents a modern standard of care in personalised medicine, supported by extensive research data and clinical evidence from numerous studies.

Our PRS calculates the combined effect of 2803 genetic variants associated with breast cancer. By combining the PRS with a person’s background (origin, age, and gender), we are able to calculate a person’s risk of developing cancer. Moreover, we provide tailored medical advice to prevent illness or promote early detection.

Approved by doctors and customers

Over 16 000 valuable insights from us

I am one of those who became a breast cancer survivor under the age of 50. But at the same time, I am very lucky because I knew about my high polygenic risk score earlier thanks to the Antegenes genetic test and started having mammograms and ultrasounds several years ago. My cancer (a subtle lobular form that did not make itself felt at all) was discovered during a regular annual check-up as a small and easily treatable cancer. Only the PRS showed a high risk of breast cancer; a later genetic test during treatment did not find any common mutations associated with cancer. Without the Antegenes test, I might not have suspected that it would be wise for me to have a breast examination before the age of 50.

Kate, 48
I never would have thought that I might have an increased risk of breast cancer – especially since there has never been any cancer in my family. Personalised breast cancer prevention gave me a clear plan to follow, including starting mammography screenings from the age of 36. I’m also committed to following the lifestyle recommendations that came with the plan to reduce my risk through healthy habits. Now I know how to take care of myself and when to start with screenings. This knowledge is truly invaluable.

Anna, 33
"Since I am younger than the age of being called for breast cancer screening, it was important for me to take a genetic risk test to find out my own genetic risk assessment of breast cancer and what I can do at a younger age to maintain my health. I found out that I have a higher risk and I’m now advised to go for a mammography screening as early as age 40 and should do it every two years. This is why I strongly encourage and recommend this kind of genetic testing – it gave me a sense of peace."

Hanna, 32

“Breast cancer is a devastating disease that affects too many people – the patients, their families, friends and colleagues. It is a disease that can often be cured if caught early and suitable treatments are prescribed. But what if there was no need for the cure? There was no diagnosis, no before or after breast cancer. What if people could live their lives safe in the knowledge that it would never happen to them.”

Lester Barr, MBE Co-Founder & Honorary President of Prevent Breast Cancer

Developed & supported by leading healthcare professionals

All our services are developed in co-operation with leading oncologists, medical geneticists and bioinformaticians across Europe and the UK.

Laura Naylor Founder of The Breast Awareness Clinic; Senior Breast Clinical Nurse Specialist

Laura Naylor Founder of The Breast Awareness Clinic; Senior Breast Clinical Nurse Specialist
Lester Barr, MBE Co-Founder & Honorary President of Prevent Breast Cancer

Lester Barr, MBE Co-Founder & Honorary President of Prevent Breast Cancer

Co-Founder & Honorary President of Prevent Breast Cancer
Prof. Gareth Evans, MB, BS, MD, FRCP, FLSW, FRCOG, ad eundem Consultant Geneticist

Prof. Gareth Evans, MB, BS, MD, FRCP, FLSW, FRCOG, ad eundem Consultant Geneticist

A Consultant at Manchester University Hospitals NHS Foundation Trust and The Christie NHS Foundation Trust, Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, particularly in neurofibromatosis and breast cancer. Professor Evans is a chair of medical genetics and cancer epidemiology at the University of Manchester. He has published 940 peer reviewed research publications, 330 as first or senior author. In the last seven years he has raised over £45 million in grants for multicentre and local studies. He is Chief Investigator on two NIHR program grants on breast cancer risk prediction and also has an NIHR RfPB grant as CI (2011). He has led a successful bid for a Nationally funded NF2 service (£7.5 million pa) that started in 2010 and is involved in the national complex NF1 service. He is the cancer prevention early detection theme leader on the NIHR Manchester Biomedical Research Centre. Professor Evans is also lead clinician on the NICE Familial Breast Cancer Guideline Group and is a trustee of BCN and the Neuro Foundation.
Peeter Padrik, MD, PhD Oncologist

Peeter Padrik, MD, PhD Oncologist peeter.padrik@antegenes.com

As one of the leading cancer specialists in Estonia, doctor Peeter Padrik has more than 30 years of experience as a clinician, researcher, leader, and healthcare manager at Tartu University Hospital. In addition to the therapy of malignant tumors, doctor Padrik is one of the pioneers in the implementation of innovative genetic information into healthcare.

RESOURCES

Latest articles and scientific publications

Fully compliant with all regulatory bodies

Personalised cancer prevention is based on genetic risk tests provided by Antegenes.

✔ CE-marked medical devices (in vitro diagnostics, IVD)
✔ Registered in the UK MHRA Registry and EUDAMED database
✔ Developed using anonymised data from the UK Biobank
✔ Antegenes is ISO 13485 certified
✔ We take your data privacy and protection very seriously